ACCESS Award
ACCESS Award supports clinical research teams testing low-cost, scalable cancer interventions to improve treatment and expand equitable access worldwide, particularly in low- and middle-income countries.
Browse similar grants
Funder: Rising Tide Foundation for Clinical Cancer Research
Due Dates: March 1, 2027 (LOI) | April 30, 2027 (Invited full proposal) | August 2027 (Award notification)
Funding Amounts: Up to USD 500,000 for up to five years, covering 50% of total project costs
Summary: Supports clinical trials of low-cost, scalable interventions that improve cancer treatment and expand equitable access worldwide.
Key Information: Patient partners must hold active governance roles; 50% co-funding must be confirmed within six months of approval.
Description
The ACCESS Award—Award to Catalyze Care through Equitable, Scalable Solutions—is run by Rising Tide Foundation for Clinical Cancer Research (RTFCCR). It supports clinical trials addressing disparities in access to effective cancer treatment, particularly in low- and middle-income countries (LMICs). Relevant approaches include AI-driven tools, drug repurposing, and dose optimization.
Trials should demonstrate clinical relevance and potential for rapid implementation, prioritize cost-effectiveness and scalability across diverse health systems, and include strategies for patient-centered outcomes. The award favors international collaborations and inclusion of LMIC centers. Evaluation emphasizes innovation, feasibility in diverse settings, meaningful patient involvement in design and dissemination, robust methodology, and clear milestones.
